Daniel Lovell, MD: abatacept in JIA
Dr. Daniel Lovell, a pediatric rheumatologist from the University of Cincinnati/Cincinnati Children's Hospital Medical Center discusses a phase-4 study looking at the effectiveness and safety of abatacept in kids with JIA.
What do you tell your patients who are considering augmentation mammoplasty? Or who question the safety of prior implants?
The Annals of Internal Medicine have published a systematic analysis at 32 studies conducted from the 1990s onward. (Citation source http://buff.ly/1O2ALp7)
Furie and coworkers presented the results of a 52-week phase II trial of anifrolumab (ANIFR), a type I interfernon (IFN) receptor antagonist in patients with lupus (SLE).
Peter Merkel, MD: ANCA-Associated Vasculitis and Maintenance of Remission
Dr. Peter Merkel from the University of Pennsylvania discusses ANCA-associated vasculitis and maintenance of remission.
Clements et al presented the results of their Scleroderma Lung Study II wherein PSS patients with interstitial lung disease were randomized to receive either 3 grams daily of mycopheonolate or 2mg/kg/day of cyclophosphamide. (Citation source: http://buff.ly/1HsOUMH)
142 patients were randomized; 106 completed the 2-year evaluation (more MMF than CYC).
Bernard Rubin, DO: The Knowledge Bowl!
Dr. Rubin, Chief of Rheumatology at Henry Ford Hospital in Detroit, Michigan, discusses the Knowledge Bowl. Teams from different universities compete in the Knowledge Bowl, a sort of 'medical Jeopardy'!
Olga Petryna, MD: oral anticoagulants agents and APS in patients undergoing joint replacement surgery
Dr. Petryna, Mt. Sinai Beth Israel Medical Center in New York, discusses use of oral anticoagulants agents and APS in patients undergoing joint replacement surgery.
Liu and coworkers from Boston presented abstract #1213, with data from the NHS II Survey. They examined 93,859 women (without RA) and their dietary data from 1991 to 2011.
Myasoedova and colleagues from the Mayo Clinic have reported their new data that demonstrates improving cardiovascular (CV) mortality rates in current RA patients treated with modern drugs.
Dr. Leonard Calabrese: Shingles and strokes, and what it means for the rheumatology community
Dr. Leonard Calabrese: following shingles, the rate of stroke goes up for 30-90 days, and the more serious the shingles, the higher the rate of stroke. See his take on what this means for the rheumatology community.
Dr. Carol Langford: MOC resources
Carol Langford, MD, discusses MOC resources available at this year's ACR annual meeting.
Dr. Orrin Troum, MD: Interested in studies on imaging for RA, and more
Orrin Troum, MD, a rheumatologist from Santa Monica, CA, discusses what he looks forward to learning more about at this year's ACR annual meeting.
Alvin Wells, MD: JAK Inhibitors, Other Interesting Studies at ACR's Annual Meeting
Dr. Alvin Wells, board-certified rheumatologist practicing in Franklin, Wisconsin, discusses what he looks forward to seeing at the 2015 ACR/ARHP Annual Scientific Meeting.
TNF blocker Induced Psoriasis: Take Home Messages
Dr. Arthur Kavanaugh Discusses RheumNow
Arthur Kavanaugh, MD, talks about how RheumNow meets the needs of today's rheumatologists and healthcare professionals.
